Finance

BaroPace Announces RelieveHFpEF-II, Its Phase I First-in-Human Trial of PressurePace™, Its Patent-Pending Pacemaker Control Algorithm for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF), Met All Primary and Secondary Endpoints

June 18, 2024

[#item_full_content]ISSAQUAH, Wash.–(BUSINESS WIRE)–BaroPace Inc announces that its First-in-Human clinical trial, RelieveHFpEF-II, met both its primary and secondary endpoints with no adverse events.